Vir Biotechnology, Inc.: ARCH Venture Fund IX, L.P. amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
ARCH Venture Fund IX, L.P. amended its Schedule 13D filing on Vir Biotechnology, Inc., according to SEC accession 0001012975-26-001020. The filing updates the fund's previously reported beneficial ownership stake in the clinical-stage immunology company. Schedule 13D amendments are required when a holder's position or intentions change materially, drawing attention from investors who track large shareholders. The specific revised share count and percentage were not detailed in the headline disclosure.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Vir Biotechnology, Inc., ARCH Venture Fund IX, L.P.